The Outlook for Pharmaceuticals in South East AsiaPublished: July 2011No. of Pages: 8Price: $3490Report SummaryThe eight p...
Focus on Biotechnology… A research-friendly environment These markets are keen toattract high value investment and have id...
second country, after Australia, in the Asia Pacific region to adopt regulations for biosimilarregistration. Competitive s...
The outlook for pharmaceuticals in south east asia
Upcoming SlideShare
Loading in …5
×

The outlook for pharmaceuticals in south east asia

685 views

Published on

The pharmaceutical markets of South East Asia are developing at markedly different speeds and are characterised by both contrasting and similar macro environments. These markets are projected to have a total pharmaceutical market value of US$77.4 billion at retail prices in 2016.

Published in: Business, News & Politics
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
685
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
16
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

The outlook for pharmaceuticals in south east asia

  1. 1. The Outlook for Pharmaceuticals in South East AsiaPublished: July 2011No. of Pages: 8Price: $3490Report SummaryThe eight pharmaceutical markets of South East Asia are developing at markedly differentspeeds and are characterised by both contrasting and similar macro environments. Thesemarkets are projected to have a total pharmaceutical market value of US$77.4 billion atretail prices in 2016.EstablishedSouth Korea is the largest market in this region and the third largest in the Asia Pacificregion. Other advanced markets such as Taiwan and Singapore are both relatively small,with growth limited by the size of these island nations. These three countries have a highpercentage of population over 65, a growing incidence of lifestyle diseases and large healthexpenditures, which present many opportunities for pharmaceutical companies. However,their governments are increasingly employing protectionist measures which deter foreigncompanies. The biologic sectors in these pharmaceutical markets in south east Asia arewitnessing rapid growth due to advanced technology capabilities, extensive R&D operationsand strong government support.EmergenIndonesia, Thailand and the Philippines are fairly large emergent pharmaceutical markets,with large populations and steadily growing economies. Despite concerns over counterfeitingand low efficacy of generic products, IPR protection and manufacturing standards areimproving thanks to effective national regulations, foreign investment and joint-ventureswith multinational companies. Malaysia and Vietnam are small pharmaceutical markets,typified by rapid economic growth, increasing foreign investment and support from nationalgovernment. These five markets have significant OTC sectors and rapidly expanding genericsectors, and present previously untapped populations for potential foreign pharmaceuticalcompanies.
  2. 2. Focus on Biotechnology… A research-friendly environment These markets are keen toattract high value investment and have identified biotechnology and biopharmaceuticalresearch as key areas. Their governments strongly advocate the growth of biotechnology.MalaysiaThe government has identified biotechnology as one the core technologies to accelerate thetransformation of the country into a knowledge-based economy by the year 2020. As aresult of this initiative, a number of new biopharmaceutical research companies haveemerged.SingaporeThe biologic sector is growing, with several large multinational companies investing a totalof US$2.0 billion to set up biologic facilities. The government is increasing its investment inbiomedical sciences research over the period 2011 to 2015.South KoreaThe biologic sector is witnessing rapid growth and many domestic companies haveexpanded their operations in 2011. Several significant competitive strategies have beencompleted in 2011.TaiwanThe government has been investing heavily in biotechnology research capability and thishas helped facilitate the growth of the biologic sector. The plan is to double the annualoutput of the sector over the period 2009 to 2013.Highlights from the regionINDONESIADue to the sheer size of the population, Indonesia cannot simply be dismissed. TheIndonesian pharmaceutical market is projected to grow at a low double-digit CAGR in USdollar terms during the forecast period, and it will be the sixth largest pharmaceuticalmarket in the Asia Pacific region by 2016. However, despite the country possessing hugemanufacturing capabilities, the complete lack of R&D in domestic companies could affect themarket, especially if IPR regulations were tightened. Although multinationals will beunhappy at the legislation requiring all drugs in the Indonesian market to have beenmanufactured in Indonesia, it could potentially reduce costs in the long term for both themanufacturer and the consumer.MALAYSIAImportant Malaysian biologic manufacturers include Bioven, CCM Duopharma, Inno Biologicsand Ninebio. The National Pharmaceutical Control Bureau (NPCB) has adopted the GuidanceDocument and Guidelines for the Registration of Biosimilars, making Malaysia only the
  3. 3. second country, after Australia, in the Asia Pacific region to adopt regulations for biosimilarregistration. Competitive strategies in Q1 2011 and 2010 include; US-based Viroproacquired Alpha Biologics; and Indian-based Avesthagen, in partnership with Inno Biologics,announced the completion of manufacturing of darbepoetin alfa, its biosimilar version ofAmgen’s Aranesp.SOUTH KOREAThe generic sector in South Korea has not taken the KORUS FTA well, as it believes it willdamage an industry that is already under strain as a result of regular government pricecuts. In order to compete, South Korean companies are investing profits from their genericsales into “super-generics”. However, this requires capital and R&D pipelines that manySouth Korean generic manufacturers simply do not possess. Competitive strategies in 2011include: Daewoong completed the construction of new a cGMP-compliant plant in Baran,Gyeonggi province; and Hanmi signed an additional licence and supply agreement withMerck for Amosartan, Cozaar XQ as Merck’s brand name.THAILANDThe Thai generic sector is growing, especially in the public sector, where the governmenthas encouraged its use over patented drugs in order to cut costs. Greater Pharma haslaunched its first generic inhaler drug for the treatment of osteoporosis, making it the firstcompany in Southeast Asia to successfully manufacture a generic version of this drug. TheThai biologic sector is very underdeveloped, but there are signs that this could change. Thegovernment-backed organisation BIOTEC has formed partnerships with both GreaterPharma and i+MED. Greater Pharma has developed the first biologic allergy vaccine inSoutheast Asia.About Us:ReportsnReports is an online library of over 100,000+ market research reports and in-depthmarket research studies & analysis of over 5000 micro markets. We provide 24/7 online andoffline support to our customers. Get in touch with us for your needs of market researchreports.Follow us on Twitter: http://twitter.com/marketsreportsOur Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689Contact:Mr.Priyank7557 Rambler road,Suite727,Dallas,TX75231Tel: +1-888-989-8004E-mail: sales@reportsnreports.comhttp://www.reportsnreports.comVisit our Market Research Blog

×